Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai’s Aricept Seen Driving 35 Percent Profit Increase For FY09

This article was originally published in PharmAsia News

Executive Summary

Eisai expects a profit increase of about 35 percent in the fiscal year just beginning, with much of the increase due to its Aricept (donepezil) to treat Alzheimer's disease. Another major Eisai sales generator is expected to be its acquisition of U.S.-based MGI Pharma and its cancer drugs. Eisai can expect a large increase in expenses for research and development, however, because of the MGI purchase. In all, Eisai's net profit for the fiscal year that began April 1 is expected to increase by 35 percent. (Click here for more - a subscription may be required

You may also be interested in...

Eisai Threatens To End Pfizer Alliance On Aricept Following Wyeth Acquisition

TOKYO - Eisai announced that it "has the right" to terminate a product development and business alliance agreement for its Alzheimer's treatment Aricept (donepezil) if Pfizer acquires Wyeth

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Shuttered US Supplement Firm Meets Recall Deadline, But Schumer Says FDA Late Cleaning Up Industry

While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts